Saturday 17 October 2026
Export BOLD’s income statement to Excel — free account
Boundless Bio, Inc.
BOLD Healthcare Biotechnology
In the quarter to June 2026, EPS fell 51.4%, free cash flow fell 76.9% and total debt fell 6.85%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.34
0.01
−0.43%
Follow BOLD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (67.86%) | (50.22%) | (46.69%) | (44.88%) |
+8 more TTM periods Free account |
|
| (50.56%) | (33.71%) | (32.02%) | (35.93%) | ||
ROIC |
0.00% | (98.41%) | (107.52%) | (107.85%) | |
Return on Tangible Assets |
(97.02%) | (63.65%) | (58.03%) | (55.24%) | |
Free Cash Flow per Share |
(2.53) | (2.12) | (2.11) | (2.35) | |
Free Cash Flow |
(56.73) | (47.60) | (47.21) | (52.70) | |
Capital Expenditures |
(0.48) | (0.49) | (0.55) | (0.59) | |
| Other line items | |||||
Cash ROIC |
(40.93%) | (21.23%) | (18.73%) | (19.20%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.88 | 0.84 | 0.80 | 0.84 | |
Depreciation/Fixed assets |
22.25 | 0.41 | 0.39 | 0.35 | |
Capex/Depreciation |
(0.22) | (0.41) | (0.44) | (0.47) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.51) | (2.10) | (2.09) | (2.33) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates